Genocea Announces Wind Down of Operations and Delisting From NASDAQ
Genocea Biosciences (Nasdaq: GNCA) announced its Board of Directors voted to wind down operations and terminate remaining employees necessary for an orderly shut down.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Genocea Biosciences (Nasdaq: GNCA) announced its Board of Directors voted to wind down operations and terminate remaining employees necessary for an orderly shut down. The company delivered notice to Nasdaq regarding its intention to voluntarily delist from the Nasdaq Capital Market, with a Form 25 filing planned around June 2, 2022. This decision follows a notification from Nasdaq that the company failed to meet compliance with Listing Rule 5450(a)(1) due to its common stock closing bid price being below $1.00 for 30 consecutive days.
Positive
- None.
Negative
- Voluntary wind down of operations.
- Termination of remaining employees.
- Intent to voluntarily delist from Nasdaq due to operational shutdown.
- Non-compliance with Nasdaq Listing Rule 5450(a)(1) due to stock price below $1.00 for 30 days.
Details
News Market Reaction – GNCA
The recorded move for GNCA in the trading session of this news was -72.69%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that its Board of Directors voted to wind down the Company’s ongoing operations and terminate the Company’s remaining employees except those deemed necessary to complete an orderly wind down.
On May 23, 2022, the Company delivered formal notice to The Nasdaq Stock Market, Inc. of its intent to voluntarily delist its Common Stock from the Nasdaq Capital Market in connection with the wind down of its operations. The Company plans to file a Form 25 with the Securities and Exchange Commission on or about June 2, 2022, to effect the voluntary delisting of the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended.
Also, on May 23, 2022, the Company received a letter from the Nasdaq Listing Qualifications department of Nasdaq notifying the Company that it was not in compliance with the requirement of Nasdaq Marketplace Rule 5450(a)(1) for continued inclusion on The Nasdaq Capital Market as a result of the closing bid price for the Company’s common stock being below
Investor Contact:
Dan Ferry
617-430-7576
daniel@lifesciadvisors.com
Media Contact:
Sarah O’Connell
soconnell@vergescientific.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.